Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on December 20, 2022, reporting events occurring on December 16, 2022. The filing addresses corporate governance changes specifically regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of H. Stewart Parker to the Board of Directors as a Class II director. Her initial term expires at the 2024 annual meeting of stockholders. She has been designated as independent and appointed to the Audit Committee and Strategic Committee.
Management Commentary and Compensation Arrangements
Ms. Parker brings extensive experience in biotechnology and biopharmaceutical leadership, including prior roles as CEO of Targeted Genetics Corporation and current board service at IMPEL Pharmaceuticals Inc. and Sangamo Therapeutics, Inc. Her compensation package includes:
- Cash Retainers: $50,000 annually for Board service, $20,000 for the Audit Committee, and $10,000 for the Strategic Committee.
- Initial Equity Grant: 37,878 shares of restricted stock granted upon appointment, vesting in three equal annual installments.
- Annual Equity Grant: Future grants calculated to equal $100,000 in value based on the closing stock price at the annual meeting, vesting in full within one year.
The Company expects to execute a standard indemnification agreement with Ms. Parker. No reportable transactions or understandings regarding her selection were disclosed.
Investor Verification Checklist
- Verify the independence status of H. Stewart Parker under Nasdaq Listing Rule 5605.
- Confirm the vesting schedule and potential dilution impact of the 37,878 restricted stock shares granted.
- Review the composition of the Audit Committee and Strategic Committee following this appointment.
- Check for any subsequent filings regarding the execution of the standard indemnification agreement.